In various animal models, PSMA-expressing prostate carcinoma xenografts were shown to have a higher take rate, to be more vascularized, to grow larger, and to have a higher rate of progression when compared to non-PSMA-expressing prostate carcinoma xenografts, including knockouts. This evidence concerns the gene FOLH1 and prostate carcinoma.